<?xml version='1.0' encoding='utf-8'?>
<document id="31833927"><sentence text="Antiviral (Hepatitis C Virus) Drug-Drug Interaction Leading to Dramatic Underestimation of Liver Function With 99mTc-Mebrofenin Hepatobiliary Scintigraphy." /><sentence text="There is a growing interest in assessment of future remnant liver function with Tc-mebrofenin hepatobiliary scintigraphy before major hepatectomy to estimate the risk of posthepatectomy liver failure" /><sentence text=" We illustrate the case of a 42-year-old woman with liver metastasis from colorectal cancer who performed hepatobiliary scintigraphy" /><sentence text=" Tc-mebrofenin clearance rate of the total liver was considerably low"><entity charOffset="1-14" id="DDI-PubMed.31833927.s4.e0" text="Tc-mebrofenin" /></sentence><sentence text=" The patient recently started a treatment for active hepatitis C with a combination of 2 new direct-acting antiviral agents (grazoprevir, elbasvir)"><entity charOffset="125-136" id="DDI-PubMed.31833927.s5.e0" text="grazoprevir" /><entity charOffset="138-146" id="DDI-PubMed.31833927.s5.e1" text="elbasvir" /><pair ddi="false" e1="DDI-PubMed.31833927.s5.e0" e2="DDI-PubMed.31833927.s5.e0" /><pair ddi="false" e1="DDI-PubMed.31833927.s5.e0" e2="DDI-PubMed.31833927.s5.e1" /></sentence><sentence text=" Apart from hypoalbuminemia or hyperbilirubinemia, physicians must be aware that drug interactions can interfere with Tc-mebrofenin liver uptake, thereby resulting in a dramatic underestimation of liver function" /><sentence text="" /></document>